181 related articles for article (PubMed ID: 19199935)
1. Antibodies for therapeutic uses and the evolution of biotechniques.
Nieri P; Donadio E; Rossi S; Adinolfi B; Podestà A
Curr Med Chem; 2009; 16(6):753-79. PubMed ID: 19199935
[TBL] [Abstract][Full Text] [Related]
2. Technological Evolution in the Development of Therapeutic Antibodies.
Fajardo-Ramírez ÓR; Ascacio-Martínez JA; Licea-Navarro AF; Villela-Martínez LM; Barrera-Saldaña HA
Rev Invest Clin; 2015; 67(3):158-69. PubMed ID: 26202739
[TBL] [Abstract][Full Text] [Related]
3. The biotechnology and applications of antibody engineering.
Rapley R
Mol Biotechnol; 1995 Apr; 3(2):139-54. PubMed ID: 7620975
[TBL] [Abstract][Full Text] [Related]
4. [Progression and direction of humanized antibody research].
Lin Y; Yan XY
Sheng Wu Gong Cheng Xue Bao; 2004 Jan; 20(1):1-5. PubMed ID: 16108479
[TBL] [Abstract][Full Text] [Related]
5. Antibodies and genetically engineered related molecules: production and purification.
Roque AC; Lowe CR; Taipa MA
Biotechnol Prog; 2004; 20(3):639-54. PubMed ID: 15176864
[TBL] [Abstract][Full Text] [Related]
6. Construction of Macaque Immune-Libraries.
Avril A; Miethe S; Hust M; Pelat T
Methods Mol Biol; 2018; 1701():83-112. PubMed ID: 29116501
[TBL] [Abstract][Full Text] [Related]
7. Engineered antibodies take center stage.
Huston JS; George AJ
Hum Antibodies; 2001; 10(3-4):127-42. PubMed ID: 11847424
[TBL] [Abstract][Full Text] [Related]
8. The therapeutic antibodies market to 2008.
Pavlou AK; Belsey MJ
Eur J Pharm Biopharm; 2005 Apr; 59(3):389-96. PubMed ID: 15760719
[TBL] [Abstract][Full Text] [Related]
9. Monoclonal antibodies: technologies for early discovery and engineering.
Kennedy PJ; Oliveira C; Granja PL; Sarmento B
Crit Rev Biotechnol; 2018 May; 38(3):394-408. PubMed ID: 28789584
[TBL] [Abstract][Full Text] [Related]
10. Antibody therapeutics, antibody engineering, and the merits of protein stability.
Demarest SJ; Glaser SM
Curr Opin Drug Discov Devel; 2008 Sep; 11(5):675-87. PubMed ID: 18729019
[TBL] [Abstract][Full Text] [Related]
11. Ribosome display: next-generation display technologies for production of antibodies in vitro.
He M; Khan F
Expert Rev Proteomics; 2005 Jun; 2(3):421-30. PubMed ID: 16000087
[TBL] [Abstract][Full Text] [Related]
12. Human antibodies from transgenic animals.
Lonberg N
Nat Biotechnol; 2005 Sep; 23(9):1117-25. PubMed ID: 16151405
[TBL] [Abstract][Full Text] [Related]
13. Tailor-made antibody therapeutics.
Chowdhury PS; Wu H
Methods; 2005 May; 36(1):11-24. PubMed ID: 15848071
[TBL] [Abstract][Full Text] [Related]
14. Engineered antibody fragments and the rise of single domains.
Holliger P; Hudson PJ
Nat Biotechnol; 2005 Sep; 23(9):1126-36. PubMed ID: 16151406
[TBL] [Abstract][Full Text] [Related]
15. Antibody engineering and modification technologies.
Filpula D
Biomol Eng; 2007 Jun; 24(2):201-15. PubMed ID: 17466589
[TBL] [Abstract][Full Text] [Related]
16. Generation of dual-variable-domain immunoglobulin molecules for dual-specific targeting.
Gu J; Ghayur T
Methods Enzymol; 2012; 502():25-41. PubMed ID: 22208980
[TBL] [Abstract][Full Text] [Related]
17. Recent progress in biomolecular engineering.
Ryu DD; Nam DH
Biotechnol Prog; 2000; 16(1):2-16. PubMed ID: 10662483
[TBL] [Abstract][Full Text] [Related]
18. Antibody engineering for the development of therapeutic antibodies.
Kim SJ; Park Y; Hong HJ
Mol Cells; 2005 Aug; 20(1):17-29. PubMed ID: 16258237
[TBL] [Abstract][Full Text] [Related]
19. Rabbit immune repertoires as sources for therapeutic monoclonal antibodies: the impact of kappa allotype-correlated variation in cysteine content on antibody libraries selected by phage display.
Popkov M; Mage RG; Alexander CB; Thundivalappil S; Barbas CF; Rader C
J Mol Biol; 2003 Jan; 325(2):325-35. PubMed ID: 12488098
[TBL] [Abstract][Full Text] [Related]
20. The rapid discovery of engineered antibodies.
Wang M; He M
IDrugs; 2007 Aug; 10(8):562-5. PubMed ID: 17665332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
